Recent advances on radionuclide labeled hypoxia-imaging agents.

Area of Science:

• Oncology
• Radiochemistry
• Medical Imaging

Background:

• Hypoxic tissue is prevalent in solid tumors, significantly reducing radiotherapy and chemotherapy efficacy.
• Non-invasive imaging techniques like PET and SPECT, coupled with radiolabeled hypoxia markers, aid in tumor delineation.
• Bioreducible organic compounds and endogenous markers are key targets for hypoxia detection.

Purpose of the Study:

• To provide an overview of recent advancements in radiolabeled hypoxia marker development.
• To discuss the application of these markers in non-invasive cancer diagnosis and treatment planning.
• To highlight challenges and progress in the field over the past decade.

Main Methods:

• Development of bioreducible organic compounds (e.g., nitroimidazoles, BnAO, ATSM) as hypoxia markers.
• Labeling of these compounds with various radionuclides (e.g., 99mTc, 123I, 18F, 64Cu).
• Investigation of endogenous hypoxia markers (e.g., CA IX, HIF-1) and associated radiolabeled tracers.

Main Results:

• Radiolabeled hypoxia markers enable non-invasive measurement of tumor hypoxia.
• These markers facilitate tumor delineation, aiding in diagnosis and treatment guidance.
• Various classes of compounds and radionuclides have been explored for hypoxia detection.

Conclusions:

• Radiolabeled hypoxia markers are vital tools for assessing tumor microenvironments.
• Continued development is essential for improving non-invasive cancer detection and personalized treatment strategies.
• Understanding hypoxia is critical for overcoming treatment resistance in solid tumors.